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Abstract: Gastrointestinal disorders, although clinically heterogeneous, share pathogenic mechanisms, including genetic susceptibility, impaired gut
barrier function, altered microbiota, and environmental triggers (infections, social and behavioral factors, epigenetic control, and diet). Gut microbiota has
been studied for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) in either children or adults, while modifiable gut microbiota
features, acting as risk and premorbid factors along the childhood-adulthood transition, have not been thoroughly investigated so far. Indeed, the
relationship between variations of the entire host/microbiota/environmental scenario and clinical phenotypes is still not fully understood. In this respect,
tracking gut dysbiosis grading may help deciphering host phenotype–genotype associations and microbiota shifts in an integrated top–down omics-based
approach within large-scale pediatric and adult case-control cohorts. Large-scale gut microbiota signatures and host inflammation patterns may be
integrated with dietary habits, under genetic and epigenetic constraints, providing gut dysbiosis profiles acting as risk predictors of IBD or IBS in
preclinical cases. Tracking dysbiosis supports new personalized/stratified IBD and IBS prevention programmes, generating Decision Support System
tools. They include (1) high risk or flare-up recurrence -omics-based dysbiosis profiles; (2) microbial and molecular biomarkers of health and disease; (3)
-omics-based pipelines for laboratory medicine diagnostics; (4) health apps for self-management of score-based dietary profiles, which can be shared with
clinicians for nutritional habit and lifestyle amendment; (5) -omics profiling data warehousing and public repositories for IBD and IBS profile
consultation. Dysbiosis-related indexes can represent novel laboratory and clinical medicine tools preventing or postponing the disease, finally interfering
with its natural history.
(Inflamm Bowel Dis 2016;22:487–504)
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Meta-omics–based Dysbiosis Profiles of
Gut Microbiota
Chronic diseases of the intestine, in particular, inflamma-
tory bowel diseases (IBDs), are a major cause of morbidity and
mortality in the developed world. Substantial evidence suggests
that luminal commensal bacteria provide an antigenic stimulus,
inducing immune response (dysregulation) and triggering the
inflammation associated with IBD onset, in genetically suscepti-
ble individuals.1–5 IBD has an established genetic component, and
genome-wide association studies have identified several immune
system (IS) pathways mutated in susceptible hosts. Some of them
are activated by infection-mediated syndromes1 or by altered cel-
lular responses.2 The relative balance of beneficial versus aggres-
sive commensal enteric microflora has been advocated to
determine mucosal homeostasis versus inflammation.3 This
inflammation results in tissue damage and cell proliferation and
infiltration, potentially changing the metabolism between normal
and diseased tissues. Recent theory has highlighted aspects of the
gut ecology, which exerts concerted actions and synergic com-
mensal responses to pathogens.4 Furthermore, because endoge-
nous and external determinants (e.g., food, antibiotic treatment,
and pathogens) modulate the gut microbiota in a complex way,
only a synergic meta-omics or systems biology approach may
provide a comprehensive understanding of the metabolic cas-
cades, during early IBD and irritable bowel syndrome (IBS) in
children. According to the developmental programming concept,
the presence of “healthy” gut microbiota in early life and through-
out childhood has a crucial role in establishing “safe” gut baseline
profiling. The shift from controlled (symbiosis) to short-tempered
inflammation (dysbiosis) preludes to overt gastrointestinal (GI)
disorders in childhood and adulthood. The stratification of GI
dysbiosis levels leads to the definition of intermediate stages,
acting as prognostic and predictive cues in the disease dynamics.5
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Because of such complexity, it was recently suggested to consider
the microbiota as a “tissue,”6 overcoming the definition of super-
organ7 and leading to acceptance of its active metabolic role. The
advent of high-throughput -omics-based methods has opened new
avenues in the knowledge of the gut ecosystem by shedding light
on its shape, modulation and interplay with microorganisms, food
or other external stimuli.8 Gut microbiota ecology is now recog-
nized as a “fingerprinting” mark capable of describing the natural
history of the disease, before its clinical manifestation, between
remission and flare-up, or in different life stages, hence allowing
recognition of early dysbiotic signatures. Epigenetic profiling in
IBD suggests that perturbation of epigenetic factors can also be
a major contributor to the development of the disease.9 -Omics
may provide cutting-edge cues for a comprehensive understand-
ing of gut dysbiosis and homeostasis imbalance through ages. The
generation of -omics-based dysbiosis profiles will reveal disease-
associated perturbations at a much earlier disease stage. Further-
more, functional profiling, in terms of microbial pathways, may
be used to generate a panel of biomarkers for disease prevention,
diagnosis, and prognosis.5,10
IBD Risk, Prevention, and
Disease Management
From a clinical point of view, IBD prevalently includes
ulcerative colitis (UC) and Crohn’s disease (CD), chronic relaps-
ing inflammatory conditions that involve large and small bowels
at the mucosa, submucosa, and muscle levels, respectively.11
Although CD and UC are distinct disorders, they share abdominal
pain, vomiting, diarrhea, rectal bleeding, and weight loss. CD and
UC present with extraintestinal manifestations (i.e., arthritis, skin
manifestations and eye diseases, anemia, pyoderma gangrenosum,
primary sclerosing cholangitis, and nonthyroidal illness syn-
drome) to different extents.12–14 Diagnosis should be based on
a combination of history, physical examination, and in general
is achieved by assessing laboratory (i.e., blood and fecal inflam-
matory markers), followed by endoscopic evaluation (esophago-
gastro-duodenoscopy and ileocolonoscopy) with multiple biopsies
of pathological lesions and Rx imaging. It is also clear that species
belonging to the symbiotic gut microbiota are involved in the
etiology and/or maintenance of inflammatory processes. Reduced
microbial diversity, increased Bacteroidetes and Enterobacteria-
ceae, and decreased Firmicutes proportions were all observed in
patients with IBD.15 A clinical study reported that Eubacterium
rectale, Bacteroides fragilis, Bacteroides vulgatus, Ruminococcus
albus, Ruminococcus callidus, Ruminococcus bromii, and Faeca-
libacterium prausnitzii were 5- to 10-fold more abundant in
healthy subjects than in patients with CD, while Enterococcus
spp., Clostridium difficile, Escherichia coli, Shigella flexneri,
and Listeria spp. were more abundant in the CD group.16 Herita-
bility of IBD seems to arise from the contribution of hundreds of
common gene variations. One hundred sixty-three IBD suscepti-
bility loci were characterized and related to 300 known genes,
associated with cytokine production, lymphocyte activation, and
response to bacterial infection, including nucleotide
oligomerization domain-2, interleukin (IL)-10 and CARD9 net-
work, suggesting a close relationship between IBD and genes
related to host–bacteria interaction and anti-inflammatory
response.17 In patients with intestinal inflammation, several
events contribute to increase bacterial exposure, including dis-
ruption of the mucus layer, dysregulation of epithelial tight junc-
tions (TJs), increased intestinal permeability, and increased
bacterial adherence to epithelial cells. In IBD, innate cells pro-
duce increased levels of pro-inflammatory cytokines (i.e., tumor
necrosis factor-a, IL-1b, IL-6, IL-12, IL-23) and chemokines.
A marked expansion of lamina propria occurs, with an increased
number of CD4+ T cells, especially pro-inflammatory T-cell
subgroups, which secrete increased levels of cytokines and che-
mokines with recruitment of leukocytes and chronic inflamma-
tion.18 Medical treatment of IBD is personalized. The choice of
drugs and route of administration (oral, rectal, injection, and
infusion) relies on several factors, including type, localization,
and severity of disease, as well as other historical and biochem-
ical prognostic factors, and patient preferences.11 Traditionally,
depending on level of severity, IBD may require immunosup-
pression to manage symptoms, and anti-inflammatory steroids
are used for controlling disease flares. Severe cases may require
surgery, such as bowel resection, strictureplasty, or temporary or
permanent colostomy or ileostomy. A relatively new treatment
option is fecal bacteriotherapy19 and fecal microbiota transplan-
tation, which have been successfully used in a few cases.20,21
Infections may contribute to IBD in some patients and, indeed,
they may benefit from antibiotic therapy.22 At present, therapeu-
tic approaches to IBD focus on contrasting the effect of specific
proinflammatory cytokines, such as tumor necrosis factor-a, in-
hibiting the entry of cells into intestinal tissues, and stimulating
T-cell activation and proliferation. Additional investigational
biological therapies include the blockade of costimulatory sig-
nals enhancing interactions between innate cells and adaptive
cells, administration of epithelial growth factors, and enhancing
tolerance through a variety of mechanisms.23
IBS Risk, Prevention, and
Disease Management
IBS affects about 5% to 20% of people worldwide.24 Diag-
nosis is based on symptoms of chronic abdominal pain, discom-
fort, bloating, and alteration of bowel habits, in the absence of
overt organic disease. Diarrhea or constipation may predominate,
or they may alternate. Although there is no cure for IBS, there are
treatments that attempt to relieve symptoms, including dietary
adjustments, medication, and psychological interventions.24 The
most common theory on IBS etiology states that IBS is a disorder
of the interaction between the brain and the GI tract, although it
has been advocated that, at least in some cases, abnormalities in
the gut microbiota are implicated in inflammation and altered
bowel function.25,26 Younger age, prolonged fever, anxiety,
depression, and history of childhood physical and psychological
abuse are often associated with the development of IBS after acute
infectious gastroenteritis.27–29
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Observations have identified a postinfectious variant of the
syndrome, possibly associated with a reduction in microbiota
diversity due to antibiotic use.30 It has been shown that patients
with IBS have fewer intestinal Bifidobacteria, Collinsella aerofa-
ciens, Coprococcus eutactus, and Clostridium cocleatum, and an
increase in Veillonella and Enterobacteriaceae.31–34 Some studies
have focused on protozoal infections as a cause of IBS.35–37 In
particular, 2 protozoa frequently observed in patients with IBS
(Blastocystis hominis and Dientamoeba fragilis) have a high prev-
alence in industrialized countries, although their importance in
IBS is still controversial.36–38
It has also been shown that a low FODMAP (Fermentable,
Oligo-, Di-, Mono-saccharides, and Polyols) diet reduces IBS
symptoms by a figure of 60% to 80%.39 This diet restricts various
carbohydrates that are poorly absorbed in the small intestine, as
well as fructose and lactose, reducing IBS symptoms in a dose-
dependent manner, while its effects on gut microbiota composi-
tion are still not fully understood.40–42
Probiotics may also have positive effects on the gut–brain
axis in IBS, by countering the effects of stress on gut immunity
and function.43 Probiotics may exert their beneficial sequels
through preserving the gut microbiota, normalizing cytokine
blood levels, improving the intestinal transit time, decreasing
small intestine permeability, and treating small intestinal bacterial
overgrowth of fermenting bacteria.44 Drugs affecting the gut sero-
tonin may reduce symptoms45 and similarly, selective serotonin
re-uptake inhibitors, frequently prescribed for panic and/or anxi-
ety disorder and depression, affect the gut and brain serotonin and
seem to improve symptoms and promote the global well-being of
some patients with IBS.46
Gut activities are locally controlled by the enteric nervous
system, a complex network of neurons along the lining of the
esophagus, stomach, small intestine, and colon and connected
with the brain by the vagus nerve, sacral parasympathetic and
sympathetic afferents (Fig. 1).47 Indeed, negative emotions (e.g.,
sadness, fear, and anger) are often associated with the develop-
ment of acute GI infections.48 Conversely, chronic GI inflamma-
tion exerts multiple effects on mood. Risk factors for the
development of IBS indeed include adverse life events, depres-
sion, and fretfulness.47 The gut microbiome synthesizes a vast
array of neuroactive molecules including true neurotransmitters,
such as serotonin, gamma-aminobutyric acid catecholamines, his-
tamine and acetylcholine, and through fermentation, a panoply of
short-chain fatty acids (SCFAs), and tryptophan, all of which have
established and unclear effects on the nervous system.49 As an
example, gamma-aminobutyric acid is synthesized by many bac-
teria, especially Lactobacilli.50 Direct and indirect effects of the
gut microbiome on the intestinal epithelium, local mucosal gut-
associated lymphoid tissue and their cytokines, enteroendocrine
cells, and enteric nervous system collaborate to affect the afferent
neuronal pathways to the brain. By means of complex interactions
on the hypothalamic–pituitary–adrenal axis and, in particular, the
central nervous system target structures, the gut microbiota influ-
ences both cognition and mood.51 When the brain is alerted to
inflammation by the IS through cytokines, the brain releases stress
hormones and neurotransmitters, leading to a variety of neurolog-
ical and psychiatric symptoms (e.g., anxiety, obsessions, compul-
sions, depression, fatigue, anhedonia, inability to sleep, etc.).
Factors increasing the intestinal barrier permeability, with the
breakdown of mucosal IgA and TJs, trigger IS abnormalities
and autoimmunity, and influence the blood–brain barrier, result-
ing in neuroimmunity.51
DISENTANGLING THE GORDIAN KNOT OF THE
IBD–IBS DISEASES
The Human Microbiota and the
“Hygiene Hypothesis”
It is generally accepted that humans are born with a sterile
gut.8 However, new evidence suggests that colonization of the GI
tract starts before birth, with the fetus ingesting amniotic fluid
containing microbes.52 Intestinal colonization is acquired during
the first months of life, with aerobic and facultative anaerobic
colonization, followed by obligate anaerobes and Bifidobacteria.53
Establishment of the gut microbiota is recognized as a complex
process influenced by factors at the level of the host and microbes
themselves.54 Humans, similar to all animals, are continuously
exposed to a broad spectrum of intestinal microbes, including
bacteria, eukaryotes, viruses, and archaea over millions of years
of evolution.55,56 High-throughput sequencing studies have
FIGURE 1. Key pathways involved in microbiota–gut–brain signaling.
The gut microbiota can modulate the gut–brain axis through many
pathways including endocrine, immune (cytokines), and neural (vagus
nerve and enteric nervous system) pathways. Gut dysbiosis leads to
increased levels of inflammatory cells/mediators. The modulation of
systemic tryptophan levels is strongly implicated in relaying the
influence of the gut microbiota to the brain. In addition, SCFAs are
neuroactive bacterial metabolites from dietary fibers possibly modu-
lating the brain and behavior.
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depicted bacterial diversity in the human microbiota and estab-
lished that healthy individuals harbor distinct communities of
bacteria dominated by Bacteroidetes and Firmicutes phyla.57–60
Although sparsely studied, eukaryotes, including fungi, protists,
and helminthes, have appeared as part of our co-evolved intestinal
community and all are components of the healthy microbiome.61
The hygiene hypothesis argues that co-evolved microbial sym-
bionts are important to human health.56 The gut microbiota com-
position has been altered dramatically by adoption of highly
hygienic habits, shifts in diet toward sterilized and processed
foods, and use of antimicrobial drugs.62 These aspects of modern
lifestyles have reduced the diversity of components of microbiota,
including bacteria,62,63 worms,56 and protists,61 altogether result-
ing in “defaunation” of the human intestine. The distribution of
autoimmune and inflammatory diseases is tightly correlated with
a transition to modern lifestyles,64 and altered microbiota accom-
panying this transition is an important risk factor for diseases.64,65
The hygiene hypothesis predicts that increased hygiene, use of
antibiotics, and sterile food preparation result in isolation of the IS
from positive microbial exposure, favoring susceptibility to
immune-mediated disorders.66 Absence of exposure to intestinal
helminths and eukaryotic commensals (i.e., Blastocystis and Di-
entamoeba) has been recognized as a risk factor for allergic/auto-
immune diseases including IBD.67–69 Several mechanisms
underlie the hygiene hypothesis: (1) lack of microbial burden in
childhood, predisposing the host to allergic disorders due to
a Th1/Th2 (T helper cells) imbalance; (2) defective maturation
of regulatory T cells, as a consequence of modern lifestyles; (3)
antigenic competition from infectious agents inhibiting responses
to weak antigens; protection from allergic diseases through mech-
anisms independent of their constitutive antigens, leading to stim-
ulation of nonantigen-specific receptors; and (4) development of
an aggressive immune response caused by genetic hyperimmunor-
eactivity, which is also triggered by dysbiosis.70
Dysbiosis in IBD and IBS: from “Extended”
Microbiota Genotypes to Tissue
Hypothesis Substantiation
Homeostasis
Gut microbiota has several metabolic functions including
production of vitamins and SCFAs, amino acid synthesis, bile
acid biotransformation, hydrolysis and fermentation of nondiges-
tible substrates and endogenous mucus.71 Bacterial fermentation
takes place in the cecum and colon, where SCFAs are absorbed,
stimulating the absorption of salts and water and exerting a trophic
effect on the intestinal epithelium (Fig. 2).72 Commensal organ-
isms prevent pathogenic colonization, competing for attachment
sites and nutrients and secreting antimicrobials.4 These mecha-
nisms are relevant for reducing the level of bacterial products
detrimental to the host (i.e., lipopolysaccharides, peptidoglycans,
bacterial CpG-DNA motifs, and superantigens).73 The indigenous
microbiota is also essential for the development of IS, directly, by
modulating regulatory T cells (i.e., T helper type 1 and 2 cells, and
T helper 17 cells),74–76 or indirectly through the immunomodulatory
effect of SCFAs.77,78 Interestingly, germ-free mice display under-
developed lymphatic systems, with fewer Peyer’s patches and iso-
lated lymphoid follicles79,80 and fewer intestinal dendritic cells.81,82
The intestinal mucosa prevents injuries by signaling the innate IS
through pattern recognition receptors, such as Toll-like receptors
and nucleotide oligomerization domain–like receptors.83 Pattern
recognition receptors recognize and bind to microbes-associated
molecular patterns,83 including lipopolysaccharides, flagellin, pep-
tidoglycan, and N-formylated peptides. Pattern recognition receptor
activation initiates NF-kB pathways, mitogen-activated protein
kinases, and caspase-dependent signaling cascades, leading to pro-
tective peptides, cytokines, chemokines, and phagocytes, triggering
apoptosis, protecting response to commensal bacteria, and trigger-
ing inflammatory response to pathogens.84
Goblet cells secrete a layer of mucus limiting the exposure of
intestinal epithelial cells to bacteria. Both the secretion of antimi-
crobial peptides (e.g., a-defensins) by Paneth cells and the produc-
tion of immunoglobulin A (IgA) provide additional protection from
luminal microbiota.82 In healthy individuals, the lamina propria
normally contains a diverse array of immune cells and secreted
cytokines, including the anti-inflammatory mediators TGF-b and
Il-10 that down-regulate immune responses. In addition, pro-
inflammatory mediators from both innate and adaptive immune
cells limit excessive entry of intestinal microbiota and defend
against pathogens.23,84 Noninflammatory defenses, including phago-
cytosis by macrophages, probably assist against bacteria entering
the lamina propria, minimizing tissue injury. A homeostatic balance
is maintained between regulatory T cells and Th1, Th2, and Th17
effector cells.23 The mucus layer, reflecting the balance between
mucus secretion and bacterial degradation, represents an obstacle
to the uptake of antigens and pro-inflammatory molecules.85 Some
evidence suggests that butyrate reinforces the colonic defense bar-
rier by inducing secretion of mucins, trefoil factors, and antimicro-
bial peptides.86 Some bacterial communities could strengthen the
barrier at TJs and may be involved in cell and tissue development,
regulating cell growth and differentiation.87 Finally, indigenous mi-
crobes shape the development of the villi microvasculature, as dem-
onstrated in germ-free animals colonized during or after the
completion of postnatal gut development (Fig. 2).88
Homeostasis Breakdown
When medications, psychological and physical stresses,
radiation, abnormal peristalsis, diet, and other factors alter the
microbiota composition, bacterial metabolic activity and/or local
community distribution are also affected, triggering dysbiosis
with a serious consequence to human health (Fig. 2).66 Chronic
inflammation may cause activation of IS, such as in obesity, type
2 diabetes, and nonalcoholic fatty liver disease. Indeed, plasma
endotoxins are higher in patients with nonalcoholic fatty liver
disease and are associated with small intestinal bacterial over-
growth and induction of hepatic Toll-like receptor-4.89,90 Hence,
gut permeability, which influences the systemic distribution of
endotoxins, may further induce metabolic endotoxemia through
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disruption of TJ proteins.91 Pathogenic infections might be facil-
itated by disruption of the intestinal ecosystem by environmental
factors. Models of Citrobacter rodentium, Campylobacter jejuni
infection, and chemically and genetically induced models of intes-
tinal inflammation have shown overgrowth of Enterobacteriaceae
in all models, indicating that inflammation-induced microbiota
changes support colonization by aero-tolerant bacteria.92 The
inflammatory response, triggered by the invading pathogen, may
function to enhance its colonization, further facilitating its viru-
lence. Thus, an alteration of the gut microbiota, initiated by host
and environmental factors, may participate in initiating diseases
caused by infectious agents (Fig. 2). Because of the inherent
plasticity of microbiota, derangement of gut barrier functions
and metabolic activity could be exploited to develop biotherapeu-
tics. Mechanisms of pre- and pro-biotics include remodeling of
microbial communities and suppression of pathogens, suppression
of pro-inflammatory factors, effects on epithelial cell differentia-
tion, and proliferation and promotion of the intestinal barrier93
with controversial effects on IBD, metabolic syndromes, immu-
nomodulation, and pathogen defense.94–96 An increase in Bifido-
bacteria induced by nutritional supplements results in improved
gut barrier, lower portal lipopolysaccharide levels, and lower
inflammatory tone in ob/ob mice (Fig. 2).97
Microbe–microbe Interactions, Blooming,
Contraction and Pathobiont Selection
The dense bacterial communities inhabiting the distal gut
compete for a limited quantity of diet-derived or host mucus–
derived carbohydrate available for fermentation.98 Diet modifica-
tions alter the microbial community structure, while maintaining
the dominance of obligate anaerobic Clostridiaceae and Bacter-
oidaceae over Enterobacteriaceae.99,100 Enterobacteriaceae are
unable to compete with obligate anaerobic bacteria for high-
energy nutrients to support their growth by fermentation, with
a disadvantage in acquiring fermentable nutrients during anaero-
bic growth. Indeed, Clostridiaceae and Bacteroidaceae use
FIGURE 2. Microbial, metabolic, and cellular mechanisms’ agents of symbiosis–dysbiosis shift under the host–microbe and microbe–microbe
interplays. Gut microbiota has several metabolic, protective, structural, and mucosal functions. When symbiosis switches to gut dysbiosis, the
imbalance involves the liver, adipose tissue, and the IS, and the gut ecosystem loses many bacterial species altering homeostasis.
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glycoside hydrolases to hydrolyze complex carbohydrates, bind-
ing proteins to recognize carbohydrates at their surface, and active
transport systems to import released oligosaccharides against
a concentration gradient. By contrast, a paucity of secreted gly-
coside hydrolases makes Enterobacteriaceae ill-equipped to
degrade complex carbohydrates, only relying on oligosaccharides
passively transported across the barrier. This might partially
explain the dominance of obligate anaerobic Clostridiaceae and
Bacteroidaceae over the facultative anaerobic Enterobacteriaceae
in healthy gut, which is reverted during inflammation, when anti-
microbials (i.e., lipocalin-2, LIP-2) and other reactive species are
released by the intestinal mucosa, favoring the propagation of
Enterobacteriaceae, which can withhold nutrients with iron or zinc
siderophore activity.101
When stimulated with pro-inflammatory molecules, the
intestinal epithelium produces antimicrobials’ reactive oxygen
species, reactive nitrogen species, and hydrogen peroxide
(H2O2), superoxide radicals (O22), and nitric oxide synthase, thus
changing dramatically the luminal environment.102–104 Nitric
oxide concentrations increased in colonic gas of patients with
IBD, modifying the luminal environment of the large bowel.105
Although the production of reactive nitrogen species and reactive
oxygen species creates a hostile environment in close proximity to
the mucosal surface, the generation of these radicals has important
side effects. In fact, as reactive nitrogen species and reactive
oxygen species are converted into non-toxic products, their by-
products, S-oxides, N-oxides, and nitrates open new metabolic
alternatives, favoring the growth of facultative anaerobic mi-
crobes including Enterobacteriaceae.98,106 Therefore, after pertur-
bations, the gut microbiota ecosystem can shift to a state of
dysbiosis, in which commensal protective function, structural
and histological role, and metabolic activities manifest impaired
concerted mechanisms (Fig. 2). This can involve overgrowth
(blooming) of otherwise under-represented or potentially harmful
bacteria (i.e., pathobionts), induced by intrusion or disappearance
of individual members (i.e., invading bacterial strains during mat-
uration of infant gut microbiota)107; shifts in relative bacterial
abundances by external stimuli; and mutation or horizontal gene
transfer.8 These alterations affect significantly the overall func-
tionality of microbiota, by enhancing the fitness of certain key-
stone pathogens or keystone stabilizers.101 Similarly, some
pathobionts such as Salmonella spp. acquire virulence factors,108
while symbiotic E. coli str. NC101, presenting with polyketide
synthase–encoding genotoxic island, adheres to gut mucosa and
blooms in patients with IBD.109 Under antibiotic-induced growth,
multidrug-resistant E. coli pathobionts (i.e., against ampicillin and
neomycin) induce sepsis-like disease in antibiotic-treated mice
through activation of the NAIP5–NLRC4 inflammasome route.110
Interestingly, Enterococcus spp., Streptococcus spp., and Gam-
maproteobacteria members undergo gut blooming during alloge-
neic hematopoietic stem cell transplantation.111 Disease-driven
blooming has also been observed for adherent and invasive E.
coli, with a higher prevalence within the ileal mucosa in patients
with CD.112
Host–microbe Signaling Interactions
Gut microbiota, with their metabolites and scaffold pro-
teins, modulate key signaling pathways involved in intestinal
mucosa inflammation, but the underlying molecular mechanisms
of host–microbiota interactions are still unclear. When the bal-
anced interaction between the GI tract and resident microbiota is
disrupted, intestinal and extraintestinal diseases such as IBD
develop.113 Genetic and environmental changes of gut microbiota
may contribute to defective host immune response. Indeed, both
quantitative and qualitative levels of microbial dysbiosis have
been reported in IBD.65 The impact of gut microbiota on gut
and systemic immune homeostasis has gained tremendous
research interest over the last few years. Particular attention has
been focused on the effects of a dysbiotic microbial community,
which is characterized by increased intestinal mucosal-adhesive
microbes and by intestinal mucosal barrier defective function.114
Imbalance of barrier integrity, with increased antigen and bacterial
uptake, is considered important to the pathophysiology of several
intestinal disorders including IBD.115 Epithelial barrier integrity is
necessary for the maintenance of correct intestinal nutrient
absorption while shielding the body from the gut lumen content,
including dietary antigens and microbial products.116,117 Epithelial
integrity can be assessed by measuring electrical resistance of the
mucosa, transmucosal flow of fluorescent molecules, or by ana-
lyzing the TJ integrity and the actin cytoskeleton shape.118 The
intestinal barrier is primarily regulated by the apical junctional
complex consisting of TJs and adherens junctions. Intestinal junc-
tions are selectively permeable, and intestinal permeability can be
increased physiologically in response to luminal nutrients or path-
ologically by mucosal immune cells and pathogens.118 Compro-
mised intestinal barrier function is associated with an array of
clinical conditions, both intestinal and systemic, including IBD
and IBS.119–121 The intestinal microbiota lives in intimate contact
with the surrounding intestinal wall and both determine the gut
health status. It is already known that enteric pathogens are able to
modify intestinal permeability by affecting specific TJ pro-
teins.114,122,123 On the other hand, commensal and probiotic bac-
teria are known to improve the intestinal barrier functioning.124
However, the presence of dysbiosis, as in patients with IBD where
the proportions of intestinal microbiota are changed, alters host
permeability by negatively influencing the junctional complex
functioning.125–128 The effects of the dysbiotic microbial commu-
nity on cell permeability, in particular on junction complexes, are
still unclear. Recent evidence suggests that microbiota modulates
the actin cytoskeleton, which has a major role in assembling and
maintaining cell junctions.122,129,130 Stress fibers (SFs) are often
the most prominent cytoskeletal structures in cells growing in
tissue culture. Attention is growing on the effect of exogenous
agents in inducing SF assembly and organization in cells. Very
little is known about the relationship between bacteria and SF
formation in the intestinal epithelial cells. The cytotoxic necrotiz-
ing factor 1, a protein from pathogenic E. coli, induces actin
reorganization into stress and retraction fibers in human epithelial
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cultured cells,131 while in contact with some E. coli strains, the
correct polarization of the epithelial cells is compromised by
a cytoskeleton rearrangement due to the assembly of the SFs.132
Further investigation is needed to analyze this issue in detail and
to test the hypothesis that altered SF formation and organization
can be used as markers of intestinal inflammation. Commensal
microbiota plays an important role in regulating the expression of
genes involved in some intestinal functions and in maintaining
immune homeostasis. MicroRNAs (miRNAs) are highly con-
served among species and seem to play a major role in both innate
and adaptive immunity, as they can control the differentiation of
various immune cells, as well as their functions. However, it is
still largely unknown how microbiota regulates miRNA expres-
sion, thereby contributing to gut homeostasis and pathogenesis of
intestinal inflammatory diseases. A recent concern has emerged
about a possible role of epigenetic mechanisms on pathogenesis
of chronic inflammatory disorders. Emerging data show that miR-
NAs are critical regulators of both innate and adaptive immune
responses133 and can suppress functional targets, including epithe-
lial barrier function regulatory genes, hence playing a critical role
in controlling the key pathogenic mechanism in IBD.133,134 To
further stress this relationship, recent results have shown that
commensal microbiota affects miRNA expression.135,136
However, to what extent miRNAs are implicated in microbiota-
mediated host gene regulation and, in particular, in the pathogen-
esis of IBD is yet unclear.
Transcriptional profiles of the mucosa actively interact with
colonic microbiota while this relationship is lacking in the colon
of patients with UC.137 Bacterial metabolism, such as butyrate
production, directly affects mucosal gene expression. Lepage
et al137 reported of bacterial crosstalk between host and microbiota
as a prominent feature of UC. The differentially overrepresented
bacteria in the microbiota of patients with UC mostly consist of
potentially pathogenic aerobic genera (Rhodococcus, Shigella/Es-
cherichia, and Stenotrophomonas). Together with an increased
level of transcripts related to the extracellular matrix, this suggests
that the presence of these bacteria could result from a defect in
barrier function in the UC gut epithelium, where they contribute
to establish a vicious circle sustaining the inflammatory process.
In particular, several butyrate-producing bacteria are more abun-
dant in healthy controls than in patients with UC. Defective
colonic epithelial oxidation of butyrate in UC has been implicated
in the disease’s pathogenesis.138 Lepage et al137 have shown a cor-
relation between the abundance of F. prausnitzii and decreased
mucosal expression of genes (e.g., MAP3K8, metallothionein)
that is associated with immune and oxidative stress response in
patients with UC, compared with their unaffected cotwins,
although the genetic background was influencing the gut micro-
biota composition and diversity. Microbiota of monozygotic twins
was more similar to that of dizygotic twins and unrelated individ-
uals, suggesting a major role of genetic background in the pres-
ence of a comparable early environment. Surprisingly, microbiota
similarity was still high in monozygotic twins discordant for UC.
However, the microbiota of unaffected siblings from UC twin
pairs exhibited higher percentages of potentially protective bacte-
ria, which could play a protective role in a deleterious environ-
ment. Unaffected siblings from UC-discordant pairs also showed
less bacterial biodiversity in respect to healthy individuals, further
supporting the heritability issue. Twins discordant for UC had
different gene expression profiles, affected patients having lower
proportions of potentially protective species.137
Together with a reduced complexity of mucosal microbiota,
the observed loss of crosstalk between host gene expression and
bacterial profiles suggests that these key elements, influencing
disease manifestation and progression, are at least in part under
genetic control. Human gut microbiota participates in epithelium
maturation, host nutrition, protection against pathogens and
regulation of gut epithelial cell proliferation,139 host energy
metabolism,140 and immune responses.76 The mucosa senses
pathogens and is unresponsive to food antigens and commensals,
thus maintaining the integrity and normal function of the intes-
tine.141 Gut immune and inflammatory responses involve the tran-
scription factor NF-kB, which through a highly conserved
regulatory pathway drives expression of genes involved in pro-
inflammatory processes at the site of infection or tissue damage,
also controlling cell survival, proliferation, and differentiation
induced by a wide range of noxious stimuli.142 NF-kB signaling
is a critical element of gut homeostatic immuno-inflammatory
function and both its deficiency and hyperactivation are linked
with chronic IBD.143–145 Lakhdari et al,146 by means of the
high-throughput functional screening of metagenomic libraries,
explored the novel NF-kB modulatory potential within human
intestinal microbiota, opening a new strategic path toward the
identification of bacterial strains and molecular patterns present-
ing potential therapeutic interest.
Modulating the Microbiota Through
Nutritional Interventions
Microbiota is modulated through diet and nutritional hab-
its147,148 even if, as the composition of gut microbiota seems to be
rather stable over long periods of adulthood,149 its richness may be
individually different. Reduced richness of gut microbiota has been
found in patients with IBD.137,150,151 Reference genome mapping
has allowed the assessment of the different phylogenetic composi-
tion of microbial communities, hence providing the description of
low gene content and high gene content individuals, displaying
significant differences in several metabolic pathways.147 In partic-
ular, the 2 groups differed in terms of SCFA production and mucus
degradation potential, hydrogen/methane/hydrogen sulphide pro-
duction potential, oxidative stress management potential, and Cam-
pylobacter/Shigella abundance, suggesting that low gene content
individuals harbor inflammation-associated microbiota. In another
study,148 the impact of an energy-restricted high-protein diet on the
gut microbiome was investigated. After consuming an energy-
restricted diet, gene richness significantly increased in the low gene
content group, while in the high gene content group, no significant
change in gene richness or diversity was found over the course of
the study. Increases in gene richness were significantly associated
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with decreases in total fat mass, hip circumference, total choles-
terol, and LDL cholesterol, supporting the hypothesis that correct-
ing microbial richness may result in improvements in metabolic
derangements.148
Given that the human microbiome influences the risk of
developing diseases,152 can we modulate the microbiome to
a health baseline pattern and will this decrease the individual risk
of developing diseases?
Research regarding the link between microbiome and
disease has the potential to revolutionize the way of screening,
diagnosing, and treating patients in the near future. It seems that
gut microbial communities and ISs co-evolve over the lifespan.
Scientists are collecting information on the way in which the
metabolic phenotypes do reflect functions encoded in host
genomes and gut microbiomes. Taken together, these observa-
tions raise the question of how the metabolism of consumed
foods affects our ISs. The dietary intake of macronutrients and
micronutrients shapes the microbial community structure,
which, in turn, changes the nutritional value of the consumed
food. The link between nutrient metabolism and IS occurs at
several levels, ranging from endocrine signaling to direct
sensing of nutrients by immune cells. For example, leptin,
a pleiotropic cytokine, regulates appetite, modulating both
innate and acquired IS,153,154 while low butyrate levels modify
the cytokine profile of Th cells155 and promote intestinal epithe-
lial barrier integrity.156 A few metabolic sensors help to coordi-
nate immune responses, when they are absorbed in the intestine
as unmodified dietary components. They interact with immune
cells or act as microbial signals in the form of microbes-
associated molecular patterns that modify local mucosal immune
responses through innate signaling pathways, such as the inflam-
masome or Toll-like receptors, as dietary components (i.e.,
SCFAs), providing signals using which the IS can monitor the
metabolic activities of microbiota.157
UNDERLYING PARADIGMATIC STRATEGIES TO
PREVENT IBD AND IBS BY GUT MICROBIOTA
DYSBIOSIS TRACKING
Using -omics Suites for Gut Dysbiosis Data
Generation and Integration: Technology
Meets Diagnostics and Clinics
Direct or indirect biomarkers of nutritional status coupled to
host and microbiota genetics and epigenetics should be investi-
gated in collaborative research, aiming at correlating IBD/IBS
onset and development from childhood to adulthood.
High-throughput technological platforms may assist in the
generation of nontargeted and targeted metabolomics (MB),
metaproteomics (MP), and metagenomics (MG) profiling from
human biospecimens to define the relationship between disease
phenotypes, host genetics and inflammation, nutritional status,
and microbiome configuration. To identify shotgun metabolite
scaffold (untargeted level, discovery) and at lower levels
(targeted, validation) IBD/IBS-related biomarkers, -omics scien-
tists should use and validate either targeted or untargeted MB,
overcoming the limitations of current applications.158,159 For
MP, shotgun label-free workflows with the minimal number of
handling steps (fast analysis) and maximal sensitivity (broad and
deep analysis) might be used for high-throughput and in-depth
characterization of fecal and mucosa metaproteomes. Handling of
samples can be performed according to procedures previously
optimized,160,161 while pipelines, such as multiple-reaction
monitoring–based or selected reaction monitoring–based targeted
MP, can be set up in homebrew workflows and, furthermore,
optimized by validation steps.162 Selected reaction monitoring is
a targeted high-throughput mass spectrometry technique for accu-
rate and robust multiplexed quantification of several tens of pro-
teins in complex samples, ideally adapted to validate sets of
biomarker candidates over large sample cohorts. This technology
has been used successfully for assessing diagnostic and prognos-
tic cancer biomarkers.162,163 Using selected reaction monitoring,
the selected signals can be confirmed and quantified in specimens
from patients with diverse forms of IBD/IBS and from controls.
The number of samples should be settled as the best compromise
between cost limitation and technical and statistical robustness164–
171 and represents an unprecedented large-scale deciphering of
MP. The MP strategy allows the analysis of whole proteomes
of half of a patient subset with CD to discover global signatures
without an a priori approach (shotgun label-free proteomics) and
to confirm these signatures in the remaining half through a high-
throughput targeted and independent approach.161 Untargeted
label-free liquid chromatography–mass spectrometry (LC-MS/
MS)–based shotgun proteomics aims at discovering remarkable
IBD/IBS-associated functional patterns in fecal microbiota and
provides a global qualitative and semiquantitative view of gene
expression levels under health and disease, without any a priori
assumption of the metabolic and cellular functions of patients
with IBD/IBS. The pipelines may rely on high-resolution tandem
MS instrumentation and benefit from recent advances in this field.
Large aliquot parts of trypsin digests of proteomes extracted from
bacterial communities can be injected into ultra performance liq-
uid chromatography and acquired MS/MS spectra interpreted by
interrogating annotated metagenomic databases, specifically re-
organized to increase the efficiency of peptide identification and
quantification (e.g., X!TandemPipeline and MassChroq open-
source softwares developed by INRA, PAPPSO Platform, http://
pappso.inra.fr/bioinfo/). Metaproteomic variables or clusters of
variables, grouping and subgrouping participants into homoge-
neous clinical phenotypes, can be extracted using different statis-
tical methods already implemented in large-scale programs (e.g.,
MetaHit) or generated ex novo.164–171
Among the host-state–associated protein signals extracted
above in fecal microbiota, the targeted proteomics approach may
select proteins and representative peptides best adapted for con-
firmation through multiple-reaction monitoring, giving priority to
peptides identified in label-free shotgun MS data and associated
with target functions with biological plausibility, in the context of
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IBD/IBS risk and onset. Similarly, in biopsies, remarkable IBD/
IBS-associated functional traits of mucosal microbiota can be
discovered by using untargeted proteomics. Label-free, gel-free
LC-MS/MS–based shotgun proteomics allow untargeted ap-
proaches on biopsies to provide a global qualitative and semi-
quantitative view of gene expression in health and disease,
without any a priori assumption of metabolic and/or cellular func-
tions accompanying IBD and IBS,172 adapting original pipelines
previously developed in animal models.163 Remarkably IBD- and
IBS-associated functional traits of mucosal microbiota can be
confirmed then by using targeted proteomic approaches. Among
the associated extracted protein signals, -omics scientists can
select proteins and their representative peptides through
multiple-reaction monitoring experiments, giving priority to
mucosal peptides targeting functions possibly associated with
IBD and IBS phenotypes, by using advanced SWATH-related
equipments, assisted by bioinformatic tools for high performing
data interpretation, before uploading mucosal metaproteomes into
advanced informatics infrastructure for secured data storage and
archiving.
Also, fecal and urine samples could be analyzed for MB
patterns, by gas chromatography–mass spectrometry, ultra perfor-
mance liquid chromatography–high-resolution MS, ultra perfor-
mance liquid chromatography–MS/MS, and proton nuclear
magnetic resonance (1H-NMR)–based processes’ protocols in
both untargeted and targeted modes (multi-analyte detection), to
define volatile and nonvolatile organic compounds. Moreover,
lipids and pro-inflammatory proteases can be detected directly
in biopsies by time-of-flight secondary ion MS imaging, again
to establish without any a priori assumption key metabolic and/
or cellular functions accompanying IBD and IBS mucosal
microenvironments.
Finally, next-generation sequencing by full-MG profiling
can confer entire microbial gene scaffolds, abundances, clusters of
orthologue groups definition, and gene representation of entire
fecal microbiota contents, providing reference sequence data-
bases, even for metaproteomes’ annotations. Indeed, full micro-
organism sequencing may represent the reference MG method (up
level, discovery), while specific gene-targeted MG (bottom level)
can be performed as a diagnostic tool for bacteria, fungus, and
parasite description. Diagnostic gene-targeted MG can cover the
gut bacterial microbiome (16S rRNA), parasitome and the so-
called eukaryotome (18S rRNA),173 and mycetome (ITS 1-4
fungal markers and 25S-28S rRNA) components. Remarkably,
bottom level MG can be used to describe phylotypes from either
fecal or mucosal microbiota, cataloguing relative operational tax-
onomic units abundances at different taxonomic levels, as micro-
biota fingerprinting in both diseased and healthy individuals.174
However, culturomics-based approaches also remain stra-
tegic to investigate the whole spectra of bacterial communities.175
Indeed, based on a culturomic-based strategy and in vitro and
in vivo pathogenicity assays, selected bacterial and yeast micro-
organisms, after harmfulness scaling characterization, can be
tested at enterocytes’ level, with respect to host inflammation
and immune response. Furthermore, invasiveness in vitro assays,
antibiotic susceptibility, biochemical and substrate utilization
tests, and virulence factor characterization can be used to define
the phenotypical characterization of bacterial and yeast strains in
either IBD or IBS gut mucosal microbiota. Therefore, the relation-
ship between gut commensal microbiota and enterocytes176,177 can
be highlighted by evaluating the effects induced by the exposure
of selected “harmful” versus “harmless” commensal bacteria on
the morphological and functional features of enterocytes by
in vitro investigation. Hence, amongst functional mucosal biomo-
lecules, pro- and anti-inflammatory oxylipins (i.e., resolvins, pro-
tectins) and poly-unsaturated fatty acid metabolites can be
characterized by hydrophilic interaction LC-MS/MS and nuclear
magnetic resonance, generating metabolic profiling reflecting
intra- or extra-cellular mucosal interplays between host and mi-
crobiota. Once isolated fractions of harmless microbes have been
characterized, their potential application in food/pharma industries
can be exploited,178 with emerging systems biology approaches
for probiotic value assessment.179 Therefore, selected microbes,
considered as harmless, can be characterized toward their poten-
tial industrial application. For selected bacterial strains, safety can
be assessed in silico and in vitro, according to the European Food
Safety Authority Guidelines (http://www.efsa.europa.eu/fr/
scdocs/doc/223.pdf; http://www.efsa.europa.eu/en/scdocs/doc/
732.pdf; http://www.efsa.europa.eu/it/search/doc/2393.pdf) and
WHO Guidelines (http://www.fda.gov/ohrms/dockets/dockets/
95s0316/95s-0316-rpt0282-tab-03-ref-19-joint-faowho-vol219.
pdf) for their further potential evaluation in food.
Furthermore, genomics and metatranscriptomics ap-
proaches may assist to evaluate host genetic signatures associated
with pediatric and adult IBD180 and IBS.181 Therefore, IBD- and
IBS-related genetic loci, methylation profiles, and miRNA expres-
sion levels in inflamed versus non-inflamed gut mucosa and ver-
sus healthy controls can be highlighted by using SNP panels of
selected loci for IBD and IBS from tissue samples. For patients
with IBD, postzygotic variations can be detected and compared
with zygotic variation in blood samples.182 Indeed, mucosal post-
zygotic modifications, induced by microbiota–tissue biological
diversity and metabolic change, could be regarded as overt IBD
profiles.182 Also, next-generation sequencing can be used to detect
de novo mutations or mosaicism in sporadic patients without
a priori hypothesis on specific mutated genes. Genome-wide
methylation and transcriptomic profiles can be used to quantify
differences in epigenetic profiles for patients with both IBS and
IBD, by comparing unaffected versus affected gut mucosa at
intraindividual and interindividual levels.
Finally, IBD and IBS candidate biomarkers in feces,
biopsies, and urines can be identified based on MB, MP, MG,
genomics profiles and metatranscriptomics discovery and confir-
mation experiments. Data from meta-omic analyses, diet and
lifestyle records can be merged in descriptive and predictive
statistical profiling to allow data mining. After defining IBD and
IBS disease-related biomarkers, the multi-level integration of
-omics data sets and markers can provide early dysbiosis profiles
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and will lay out data, metadata structures, and algorithms needed
for designing a multi-omics systems biology-based prevention
program for either IBD or IBS.
The MG, MB, MP, genomics, transcriptomics and phe-
nomics data sets, integrated into unified resources, such as web
portals or a centralized bioinformatic service core, available to
researchers and clinicians, because compliant with existing
standards (http://www.isa-tools.org/), enable the deployment of
the predictive profiling into effective prevention programs. A
standard for generation, storage, and annotation of -omics data
can be adopted, with a proactive action for alliance with the bio-
sharing and translational resource communities (ISA Commons,
RDA Alliance, and tranSMART), in order that data and metadata
formatting complies with most used schemes and sample meta-
data guidelines (e.g., Sequence Read Archive and Genomic
Standards Consortium) and are submitted to on-line repositories
including EBI MG services. In particular, we propose to adopt the
open source ISA metadata tracking tools for the already available
schemes for proteomics and possibly introducing ISA compliant
descriptors (http://www.isa-tools.org/). In the derivation of statis-
tically significant associations between MB, MP, MG data and
clinical, physiological, immunological, genetic, and epigenetic
data, standards also need to be adopted to describe the results
for basic and advanced data analysis (e.g., richness, composition,
and biodiversity, as well as meta-omics profiles).
The main expected result is a dysbiosis score-based tool
(model and biomarkers, possibly described as multi-level net-
work) aimed at predicting different gut dysbiotic types/profiles
relying on multilevel -omics data, integrated with IBD and IBS
clinical (phenomics) information. Starting from the unified
resource, early dysbiotic patterns (e.g., trajectories leading to
dysbiosis) will be differentially analyzed and stratified for main
determinants of variability. The tool will use the identified
predictive biomarkers and the disease phenotype to derive a score
describing dysbiosis status on a continuous scale. Biological-
clinical evaluation of the meta-omics profiles and additional data
testing will be used in the validation phase. The resultant data sets
will be deposited in annotated (“curated”) searchable databases,
overcoming the issues generated by the difficult utilization of “big
data” in translational preventive medicine (Fig. 4).183 A major
challenge will be to obtain cellular and molecular biomarkers
for profiling of the innate and adaptive ISs, including biomarkers
of mucosa-associated barrier function.
Given the small quantities of biomaterials available from
biopsy specimens, especially in children, international clinical and
-omics consortia will be necessary to foster the advancement of
dysbiosis tracking as a preventive strategy or therapeutic recom-
mendation in IBD and IBS control.113 Clearly, microbiota com-
position and activity need to be complemented by host metabolic
phenotype maps to unveil dysbiosis spectra in high-risk subjects
and produce reliable disease risk assessment.184 The idea is grow-
ing that metabolite diversity, possibly exceeding gut microbial
diversity, should be investigated with respect to endogenous
inflammation, mediated by environmental stimuli, developing
a new frontier of metabolics-immunology integrated at the level
of microbial or microbial-mammalian co-metabolites and host
response in the onset and development of disease (Fig. 3).185 Also
direct and indirect biomarkers of nutritional status186 coupled with
host and microbiota genetics and epigenetics should be investi-
gated to fully consider IBD/IBS onset and development from
childhood through adulthood.
Tracking of gut dysbiosis, assisted by assembled evidence
from host genetics, host transcriptomics, gut microbiota compo-
sition and function, and their interactions will contribute to
develop novel preventive concepts, discover dysbiosis bio-
markers, and provide innovative tools for IBD/IBS risk detection,
targeted prevention, and therapy in the framework of a system
medicine approach. To fill existing gaps into the new integrated
-omics framework on the gut microbiome and IBD/IBS host
inflammation mechanisms, researchers and clinicians should
extensively investigate disease indicators.
To fill existing gaps into this new -omics framework on the
gut microbiome and IBD/IBS inflammation mechanisms, an
integrated approach is needed, including discrete characterization
of microbiome gene clusters,185 tissue-targeted metabolite and
lipidomic mapping, selectively fungi–host and fungi–prokaryotes
interaction pathways by MS imaging, transcriptional host and
microbial networks but also small-molecule phenocopies, gene
clusters, important actors in the host–microbiota interplay, testing
microbes, and metabolites as the new candidates of dysbiotic
tracking.187–190
Laboratory, Clinical Data, and Knowledge
Management: From Biobank to Databank
Through Open Access Integrated Data
To manage big data, anonymized clinical contents (phe-
nomics) should be made available by setting specific Open Data
endpoints able to monitor data sources (data producing facility,
data type, and data format) and data processing (data collection,
filtering, transformation, sharing and routing functions required to
classify and assign disease phenotypes) before integration.
The data management must guarantee also data sharing,
open (or not) mining, platform curation and preservation, as
previously experimented by the Metagenopolis project (http://
www.mgps.eu/index.php?id¼homepage). A preliminary design
of the proposed data flow, available to both clinicians and scien-
tists, is provided in Figure 4. A centralized “datastore” can collect
and filter data from data generators (-omics, meta-omics, diagnos-
tic laboratories, and clinical centers, through electronic case report
forms) and can communicate them to the data analysis platforms
(Fig. 4). In this respect, Bambino Gesù Children’s Hospital
(OPBG) has started reference work for the description of extended
microbiota genotypes associated with a programming phase during
growth and chronic diseases.191 The initiative represents one of the
first attempts to translate into the clinical practice MG and more
generally meta-omics–based diagnostic pipelines to provide com-
positional and functional signatures of gut-associated diseases.192
Currently, meta-omics integrated analyses on neonate/children gut
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microbiota under physiological and pathological conditions
(“programming,” dysbiosis, and disease) are routinely performed
at OPBG. The comprehension of a “healthy” gut microbiome in
early life stages, immediately after birth and through the entire
childhood, has a crucial role in establishing a good nutritional
practice in childcare and pediatrics, especially in endorsing
healthy development and aging. Although on adults several stud-
ies on gut microbiota have been already produced, much work
still remains to be carried out to improve the understanding of its
role in neonates and children. The OPBG gut microbiota activities
aim at describing endophenotypes associated with physiological
conditions (symbiosis) and different gut-related diseases,
FIGURE 3. Scheme of the -omics pipelines to unveil dysbiosis patterns. This scheme reports the different -omics pipelines, the type of samples,
and the goals of each activity aiming at describing gut dysbiosis.
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including intermediate states of dysbiosis leading to disease, by
providing individualized microbiota signatures (e.g., operational
taxonomic units description and enterotypes) and function-related
meta-omics charts (e.g., microbial protein clusters of orthologue
groups’ patterns and metabotypes) of “healthy” and diseased
children. Once the enterotypes have been identified and associated
with endophenotypes, the meta-omics charts are used to identify
functional factors leading to gut perturbation under different
conditions, highlighting differences among healthy, dysbiotic,
and diseased statuses. Differences in the gut microbiome under
physiological or clinical conditions are selected as potential clues
of perturbation/disease.
At a local level, OPBG has endorsed a team of leading
clinicians, -omic scientists, and laboratory technicians to establish
an Italian consortium for systems medicine aiming to intervene
into medical research, diagnostic solutions, and clinical manage-
ment of chronic diseases with onset at the age of early develop-
ment. Scientists at OPBG have developed the concept of
“extended genotype” aiming to produce operational pipelines
for diagnostic routine toward non-invasive microbial ecology di-
agnostics and have developed original pipelines for meta-omics
integrated studies in pediatric diseases163 (http://www.cell.com/
abstract/S0092–8674(12)00629–0#Comments). The clinical
OBPG framework nowadays allows the clinical interpretation of
gut dysfunctions, critically evaluating relationships between gut
and other organs or districts (e.g., mouth, upper and lower respi-
ratory tract, liver, adipose tissue, and brain). The symbiotic and
dysbiotic cohorts (reference individuals) provide a large number
of samples that constitute a reference pediatric biological bank,
available to national and international consortia. All meta-omics
data associated with patient fingerprinting are integrated by co-
correlations. The OPBG Biobank presently includes more than
3000 fecal and 500 biopsy samples collected from inpatients
affected by different pediatric diseases that are processed to assess
gut and other site microbiota alterations and provide disease-
related signatures (nonalcoholic fatty liver disease, cystic fibrosis,
obesity, metabolic diseases, juvenile idiopathic arthritis, etc.).193
From Dysbiosis Integrated Data to Predictive
IBD and IBS Signatures: An mHealth
App Support
The integration of meta-omics and phenomics with nutrige-
nomics (diet) and foodomics (food matrix) profiling is used to
create a more comprehensive and exhaustive score-based tool (i.e.,
dysbiosis scale) for the prediction of gut inflammation types,
corrected for all variability determinants (single patient path and
-omics data multiplatforms, multiplatform Health app [mHealth
app]). The signatures are used to target the disease network analysis
(integrative network analysis by multilevel methods). This analysis
allows the definition of most informative biomarker sets required
for predicting disease onset and increasing the model fitness. The
predictive signatures of IBS and IBD are using defined risk groups
(e.g., I level familiar pedigree or relatives),194,195 considering age-
specific factors as appropriate (Fig. 5, Panel A). Accordingly, an
FIGURE 4. Workflow of -omics data for IBD and IBS dysbiosis tracking: datastore, data trafficking, and derived data warehousing.
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mHealth app for dysbiosis detection (mDys) will be upgraded into
an mHealth demonstrator as a novel tool for advanced prevention
strategies. The demonstrators will be used for self-management of
score-based dietary profiles, as support to personalized dietary in-
terventions, and shared with clinicians as a possible prevention tool
prototype (pDys). The app will provide feedback to patients at risk
and in remissions to plan microbiota modification-based interven-
tion. Hence, the prevention program may foresee a multistep
screening approach including laboratory assays (targeted-omics
assay) easily associable to discrete/defined biomarkers. In addition,
this program will allow the identification of individuals with overt
dysbiosis profiles, followed by more specific and complex assays,
FIGURE 5. Dysbiosis patterns for preventive programs. Panel A. Methodologies applied to describe the dysbiosis scale. Panel B. Schematic diagram
describing the clinical strategy for recruitment of IBD and IBS individuals at higher risk, -omics–based screening of at-risk individuals, and design of
dedicated dietary prevention trials.
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also assisted by the mHealth app. Finally, the program will make
possible to track dysbiosis before overt clinical disease, when clini-
cally unaffected individuals still benefit from preventive strategies,
and to avoid further flare-ups in patients in remission (Fig. 5, Panel B).
To validate the predictive ability of the identified bio-
markers to correctly assess the risk of IBD, patients’ first-degree
relatives should also be enrolled.
For recruiting a cohort of subjects at increased IBS risk,
children and adults with general GI symptoms could be selected,
screened at first step by using questionnaires designed by
pediatricians and gastroenterologists. Prevention programs, based
on diet modulation in individuals at high risk, could be designed
and assessed, also using dietary self-management through the
pDys app, to generate score-based dietary advice. Then, data
could be collected at each time point during dietary trials to assess
potential changes in dietary habits, in relation to evolution of
overt disease IBD phenotypes and clinical symptoms. For the
IBS-risk groups, characterized by strong psychological risk co-
factors, possibly because of microbiota alterations along the gut–
brain axis, the impact of home-based cognitive therapies in the
symptom amelioration and in the disease prevention should also
be considered (Fig. 5, Panel B).
Conclusions and Clinical Perspectives
IBD and IBS share a number of common causative features
consisting of genetic predisposition, impaired gut barrier function,
altered microbiota, and environmental triggers. Clinical heteroge-
neity within IBD and IBS has long been recognized, and evidence
is growing that IS dysregulation, gut microbiota dysbiosis, and
genetic constraints could explain differential age-dependent
phenotypes. With reference to host-gut microbiota interplay, we
propose ecological dynamics and functional alterations of gut
microbiota as triggering factors of disease onset and progression.
The herein proposed dysbiosis tracking will enable the
identification of (1) profiles describing gut perturbation and
inflammation, (2) possible risk predictors of IBD or IBS, (3)
reservoir of disease-specific, and (4) health-specific biomarker
candidates. Through the application of tools to analyze bio-
markers reflecting the complex molecular events taking place in
the early phases of IBD and IBS in the routine clinical setting, we
suggest to identify high-risk individuals through a multi-omics
approach, overcoming the current lack of prevention programs
tackling IBD and IBS.
We aim to assess the efficacy of targeted dietary inter-
ventions in restoring healthy microbiota function, the dysbiotic
variations of which trigger the physio-pathological onset of the
disease. The omics-based predictive assays and targeted dietary
interventions may have the potential of developing prevention
programs. A recent survey indicates that patients with IBS are
interested in learning about diets limiting IBS symptoms.196 We
expect a similar reaction in individuals/parents recently informed
about their own/their children’s risk of developing a severe
chronic condition such as IBS/IBD. However, poor compliance
to dietary indications, especially in the long term, is well known.
To promote adherence, virtuous behaviors can be improved by
means of mHealth Apps, providing personalized indications.
A scoring system for dietary patterns, linked with -omic
signatures, can be regarded as a “new generation” predictor of
IBD/IBS development and evolution. Dietary profiles can be
made available through a web-interface by an App tool, targeting
personalized management of dietary profiles and supporting data
collection for integrative multi-step diagnosis and targeted dietary
modulation.
This approach may contribute to develop novel preventive
concepts, to discover new dysbiosis biomarkers, and to provide
innovative tools for IBD and IBS risk detection, targeted-
prevention, and therapy.
The big -omic data deposited in annotated searchable data-
bases, under sharing conditions, allow data consultation by clin-
ical and scientific communities. In this way, international -omics
scientist and clinician consortia will forward the advancement of
dysbiosis tracking as preventive strategy and therapeutic recom-
mendation for controlling IBD and IBS.
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